Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals.
Vogel M, Ahlenstiel G, Hintsche B, Fenske S, Trein A, Lutz T, Schürmann D, Stephan C, Khaykin P, Bickel M, Mayr C, Baumgarten A, Buggisch P, Klinker H, John C, Gölz J, Staszewski S, Rockstroh JK. Vogel M, et al. Among authors: fenske s. Eur J Med Res. 2010 Mar 30;15(3):102-11. doi: 10.1186/2047-783x-15-3-102. Eur J Med Res. 2010. PMID: 20452894 Free PMC article. Clinical Trial.
Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group.
Rockstroh JK, Bergmann F, Wiesel W, Rieke A, Thiesen A, Fätkenheuer G, Oette M, Carls H, Fenske S, Nadler M, Knechten H. Rockstroh JK, et al. Among authors: fenske s. AIDS. 2000 Jun 16;14(9):1181-5. doi: 10.1097/00002030-200006160-00015. AIDS. 2000. PMID: 10894282 Clinical Trial.
Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort.
Koegl C, Wolf E, Hanhoff N, Jessen H, Schewe K, Rausch M, Goelz J, Goetzenich A, Knechten H, Jaeger H, Becker W, Becker-Boost I, Berzow D, Beiniek B, Brust J, Shcuster D, Dupke S, Fenske S, Gellermann HJ, Gippert R, Hartmann P, Hintsche B, Jaeger H, Jaegel-Guedes E, Jessen H, Gölz J, Koelzsch J, Helm EB, Knecht G, Knechten H, Lochet I, Gute P, Mauruschat S, Mauss S, Miasnikov V, Mosthaf FA, Rausch M, Freiwald M, Reuter B, Schalk HM, Schappert B, Schnaitmann E, Schneider I, Schüler-Maué W, Schuler C, Seidel T, Starke W, Ulmer A, Müller M, Weitner I, Schewe K, Zamani C, Hanmond A, Ross K, Bottlaender A, Hoffmann C, Dix A, Schneidewind A, Lademann M; Ac-DAG Study Group. Koegl C, et al. Among authors: fenske s. Eur J Med Res. 2009 Jul 22;14(7):277-83. doi: 10.1186/2047-783x-14-7-277. Eur J Med Res. 2009. PMID: 19661009 Free PMC article.
Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy.
Lichterfeld M, Nischalke HD, Bergmann F, Wiesel W, Rieke A, Theisen A, Fätkenheuer G, Oette M, Carls H, Fenske S, Nadler M, Knechten H, Wasmuth JC, Rockstroh JK. Lichterfeld M, et al. Among authors: fenske s. HIV Med. 2002 Jan;3(1):37-43. doi: 10.1046/j.1464-2662.2001.00091.x. HIV Med. 2002. PMID: 12059949 Free article. Clinical Trial.
A highly virulent variant of HIV-1 circulating in the Netherlands.
Wymant C, Bezemer D, Blanquart F, Ferretti L, Gall A, Hall M, Golubchik T, Bakker M, Ong SH, Zhao L, Bonsall D, de Cesare M, MacIntyre-Cockett G, Abeler-Dörner L, Albert J, Bannert N, Fellay J, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos RD, Laeyendecker O, Meyer L, Porter K, Ristola M, van Sighem A, Berkhout B, Kellam P, Cornelissen M, Reiss P, Fraser C; Netherlands ATHENA HIV Observational Cohort†; BEEHIVE Collaboration†. Wymant C, et al. Science. 2022 Feb 4;375(6580):540-545. doi: 10.1126/science.abk1688. Epub 2022 Feb 3. Science. 2022. PMID: 35113714 Free article.
Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.
Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, Harrer T, Esser S, Bogner JR, Brockmeyer NH, Bieniek B, Rockstroh J, Hoffmann C, Stoehr A, Michalik C, Dlugay V, Jetter A, Knechten H, Klinker H, Skaletz-Rorowski A, Fätkenheuer G, Egan D, Back DJ, Owen A; German Competence Network for HIV/AIDS Coordinators. Wyen C, et al. J Antimicrob Chemother. 2011 Sep;66(9):2092-8. doi: 10.1093/jac/dkr272. Epub 2011 Jun 29. J Antimicrob Chemother. 2011. PMID: 21715435 Free article.
105 results